Table 1.
Baseline characteristics for the overall sample and subsample with in-clinic follow-up after 1 year.
|
Total sample (N = 114) |
Sample with in-clinic follow-up (n = 72) |
|
|---|---|---|
| FU C3 assessments, M (SD) [range] | 11.7 (3.2), [2–15] | 12.8 (1.8), [2–15]* |
| N month 0.25/1/2/3 | 101/104/106/104 | 64/68/70/69 |
| Age, M (SD) | 77.6 (5.0) | 77.8 (4.9) |
| Female, n (%) | 70 (67.3%) | 42 (60%) |
| Years of Education, M (SD) | 16.5 (2.7) | 16.3 (2.8) |
| Global CDR, 0/0.50 | 105/9 | 66/6 |
| MMSE score, M (SD) | 29.1 (1.3) | 29.2 (1.2) |
| PACC5 score, M (SD) | 0.22 (0.76) | 0.29 (0.73) |
| PiB-PET years since C3 baseline | −0.99 ± 1.6 | −0.68 ± 1.7 |
| Global cortical amyloid (DVR) | 1.21 ± 0.23 | 1.22 ± 0.25 |
| Aβ status | 81 Aβ−/33 Aβ+ | 50 Aβ−/22 Aβ+ |
| N | 105 | 66 |
| FTP-PET years since C3 baseline | −0.62 ± 1.1 | −0.34 ± 1.2 |
| FTP-PET ET Tau (SUVR, PVC) | 1.38 ± 0.28 | 1.39 ± 0.27 |
| FTP-PET IT Tau (SUVR, PVC) | 1.50 ± 0.18 | 1.50 ± 0.16 |
N.B.
*
p < 0.001.
C3, Computerized Cognitive Composite; CDR, Clinical Dementia Rating scale; MMSE, Mini-Mental State Examination; PACC-5, Preclinical Alzheimer's Cognitive Composite-−5; PET, Positron-emission tomography; PiB, 11C-Pittsburg Compound-B; Aβ, Amyloid-beta; DVR, distribution volume ratio; FTP, 18F-Flortaucipir; SUVR, Standardized uptake value ratio; PVC, Partial volume corrected.